Title (en)

ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS

Title (de)

ANTIKÖRPER, DIE IMMUNOSPEZIFISCH AN TRAIL-REZEPTOREN BINDEN

Title (fr)

ANTICORPS SE FIXANT DE FACON IMMUNOSPECIFIQUE A DES RECEPTEURS TRAIL

Publication

EP 1534336 A4 20051214 (EN)

Application

EP 03788476 A 20030815

Priority

- US 0325457 W 20030815
- US 40338202 P 20020815
- US 42573002 P 20021113
- US 46805003 P 20030506

Abstract (en)

[origin: WO2004016753A2] The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

IPC 1-7

A61K 39/395; C07K 16/00; C07K 16/28

IPC 8 full level

C07K 16/28 (2006.01)

CPC (source: EP)

A61K 39/39558 (2013.01); **C07K 16/2878** (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)

Citation (search report)

- [Y] WO 0209755 A2 20020207 - GENENTECH INC [US], et al
- [A] WO 9937684 A1 19990729 - GENENTECH INC [US]
- [Y] MITSIADES CONSTANTINE S ET AL: "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications", BLOOD, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 795 - 804, XP002336504, ISSN: 0006-4971
- [Y] NIMMANAPALLI R ET AL: "Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. FEB 2001, vol. 7, no. 2, February 2001 (2001-02-01), pages 350 - 357, XP002336505, ISSN: 1078-0432
- [Y] FULDA SIMONE ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), published online 15.07.2002, pages 808 - 815, XP002336506, ISSN: 1078-8956
- [Y] INOUE H ET AL: "HISTONE DEACETYLASE INHIBITORS SENSITIZE HUMAN COLONIC ADENOCARCINOMA CELL LINES TO TNF-RELATED APOPTOSIS INDUCING LIGAND-MEDIATED APOPTOSIS", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 9, no. 5, May 2002 (2002-05-01), pages 521 - 525, XP009007225, ISSN: 1107-3756
- [Y] DEJOSEZ M ET AL: "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 11, November 2000 (2000-11-01), pages 1127 - 1136, XP002336507, ISSN: 1350-9047
- [Y] CHUNTHARAPAI A ET AL: "Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2001, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 4891 - 4898, XP002336508, ISSN: 0022-1767
- [Y] GLINIAK B ET AL: "Enhanced therapeutic efficacy of TRAIL/Apo2L in combination with CPT-11 in the treatment of human tumor xenografts", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 41, 1 April 2000 (2000-04-01), pages 70, XP002207071
- [Y] GLINIAK B ET AL: "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND'S ANTITUMORACITVITY IN VIVO IS ENHANCED BY THE CHEMOTHERAPEUTIC AGENT CPT-11", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6153 - 6158, XP000941885, ISSN: 0008-5472
- [PA] DILLMAN ROBERT O: "Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 15 AUG 2002, vol. 20, no. 16, 15 August 2002 (2002-08-15), pages 3545 - 3557, XP009050751, ISSN: 0732-183X
- [A] ROEHN TILL A ET AL: "CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release", ONCOGENE, vol. 20, no. 31, 12 July 2001 (2001-07-12), pages 4128 - 4137, XP002336509, ISSN: 0950-9232
- See references of WO 2004016753A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004016753 A2 20040226; **WO 2004016753 A3 20040617**; AU 2003259835 A1 20040303; AU 2003259835 A8 20040303; CA 2494372 A1 20040226; CA 2494372 C 20130528; EP 1534336 A2 20050601; EP 1534336 A4 20051214

DOCDB simple family (application)

US 0325457 W 20030815; AU 2003259835 A 20030815; CA 2494372 A 20030815; EP 03788476 A 20030815